Generic drug
Tofacitinib price, strengths & recalls
Generic of Xeljanz
Pharmacies pay $62.63 for 30 tablets of Tofacitinib 11 mg (24 hr) extended-release tablet this week, and from $16.86 to $62.63 across its 2 priced strengths and forms. 22 manufacturers make it. Its official label last changed on July 24, 2026.
Generic- Fair cash price
- $82.52
- Strengths
- 2
- Makers
- 22
- Updated
- Nov 11
Tofacitinib price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay | ||
|---|---|---|---|---|
| 11 mg (24 hr) extended-release tablet | $2.09 | $62.63 / 30 tablets | ||
| 1 mg/mL oral solution | Not priced this week | |||
| 5 mg tablet | $0.5619 | $16.86 / 30 tablets | ||
Brand names of tofacitinib
A brand and its generic share the active ingredient; the generic is almost always far cheaper.
Medicare negotiated price
Xeljanz was selected for Medicare price negotiation. Its negotiated price takes effect on January 1, 2028; the price itself is published by the end of November 2026.
What this means for patients
- The negotiated price is what Medicare Part D plans pay for the drug - not your price at the counter.
- What you pay depends on your plan's copay or coinsurance and where you are in the year. Coinsurance (a percentage) falls with the price; a flat copay may not change at all.
- Out-of-pocket costs for Part D drugs are capped each year ($2,100 in 2026), whatever the drug.
- If you don't have Medicare, the negotiated price doesn't apply to you - check the fair cash price above instead.
Supply status: shortages & recalls
What people paid for Tofacitinib
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use TOFACITINIB EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for TOFACITINIB EXTENDED-RELEASE TABLETS. TOFACITINIB extended-release tablets, for oral use Initial U.S. Approval: 2012
WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS, and THROMBOSIS
SERIOUS INFECTIONS
Patients treated with tofacitinib extended-release tablets are at increased risk for developing serious bacterial, fungal, viral, and opportunistic infections, including tuberculosis (TB), that may lead to hospitalization or death [see Warnings and Precautions (5.1) and Adverse Reactions (6.1)]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Reported infections included:
Active TB, which may present with pulmonary or extrapulmonary disease. Patients should be tested for latent TB before tofacitinib extended-release tablets use and during therapy. Treatment for latent infection should be initiated prior to tofacitinib extended-release tablets use.
Invasive fungal infections, including cryptococcosis and pneumocystosis. Patients with invasive fungal infections may present with disseminated, rather than localized, disease.
Bacterial, viral, including herpes zoster, and other infections due to opportunistic pathogens.
The risks and benefits of tofacitinib extended-release tablets treatment should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.
Patients should be closely monitored for the development of signs and symptoms of infection during and after tofacitinib extended-release tablets treatment, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy. If a serious infection develops, interrupt tofacitinib extended-release tablets until the infection is controlled [see Warnings and Precautions (5.1)].
MORTALITY
In a large, randomized, postmarketing safety study in rheumatoid arthritis (RA) patients 50 years of age and older with at least one cardiovascular (CV) risk factor comparing XELJANZ tablets 5 mg or 10 mg twice a day to tumor necrosis factor (TNF) blockers, a higher rate of all-cause mortality, including sudden CV death, was observed with XELJANZ tablets 5 mg or 10 mg twice a day [see Warnings and Precautions (5.2)]. XELJANZ 10 mg twice daily and tofacitinib extended-release tablets 22 mg once daily dosages are not recommended for the treatment of RA, psoriatic arthritis (PsA), or ankylosing spondylitis (AS) [see Dosage and Administration (2.3)].
MALIGNANCIES
Malignancies, including lymphomas and solid tumors, have occurred in patients treated with XELJANZ and other Janus kinase inhibitors used to treat inflammatory conditions. In RA patients, a higher rate of malignancies (excluding non-melanoma skin cancer (NMSC)) was observed in patients treated with XELJANZ tablets 5 mg or 10 mg twice a day compared with TNF blockers [see Warnings and Precautions (5.3)].
Lymphomas and lung cancers were observed at a higher rate in patients treated with XELJANZ tablets 5 mg or 10 mg twice a day in RA patients compared to those treated with TNF blockers. Patients who are current or past smokers are at additional increased risk.
MAJOR ADVERSE CARDIOVASCULAR EVENTS
RA patients 50 years of age and older with at least one cardiovascular risk factor, treated with XELJANZ tablets 5 mg or 10 mg twice daily, had a higher rate of major adverse cardiovascular events (MACE) (defined as cardiovascular death, myocardial infarction, and stroke), compared to those treated with TNF blockers. Patients who are current or past smokers are at additional increased risk. Discontinue tofacitinib extended-release tablets in patients that have experienced a myocardial infarction or stroke [see Warnings and Precautions (5.4)].
THROMBOSIS
Thrombosis, including pulmonary embolism, deep venous thrombosis, and arterial thrombosis have occurred in patients treated with XELJANZ and other Janus kinase inhibitors used to treat inflammatory conditions. Many of these events were serious and some resulted in death. RA patients 50 years of age and older with at least one cardiovascular risk factor treated with XELJANZ tablets 5 mg or 10 mg twice daily compared to TNF blockers had an observed increase in incidence of these events. Avoid tofacitinib extended-release tablets in patients at risk. Discontinue tofacitinib extended-release tablets and promptly evaluate patients with symptoms of thrombosis [see Warnings and Precautions (5.5)].
WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR
EVENTS, and THROMBOSIS
See full prescribing information for complete boxed warning.
Increased risk of serious bacterial, fungal, viral, and opportunistic infections, including tuberculosis (TB), leading to hospitalization or death. Interrupt tofacitinib extended-release tablets treatment if serious infection occurs until the infection is controlled. Test for latent TB before and during therapy; treat latent TB prior to use. Monitor all patients for active TB during treatment, even patients with initial negative latent TB test. (5.1)
Higher rate of all-cause mortality, including sudden cardiovascular (CV) death with XELJANZ vs. TNF blockers in rheumatoid arthritis (RA) patients. (5.2)
Malignancies have occurred in patients treated with XELJANZ. Higher rate of lymphomas and lung cancers with XELJANZ vs. TNF blockers in RA patients. (5.3)
Higher rate of major adverse CV events (defined as CV death, myocardial infarction, and stroke) with XELJANZ vs. TNF blockers in RA patients. (5.4)
Thrombosis has occurred in patients treated with XELJANZ. Increased incidence of pulmonary embolism, venous and arterial thrombosis with XELJANZ vs. TNF blockers in RA patients. (5.5)
Recent major changes (as listed on the label)
Boxed Warning | 10/2025 |
Indications and Usage, Psoriatic Arthritis (1.2) | 10/2025 |
Warnings and Precautions, Serious Infections (5.1) | 03/2026 |
Warnings and Precautions, Hypoglycemia in Patients with Diabetes (5.8) | 6/2026 |
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA203214 · Pf Prism Cv
- First approved
- November 6, 2012 (14 years ago)
- Latest approved change
- September 16, 2026
- Approved label
- PDF, Sep 22, 2026
- Generic makers
- 21 approved generic applications on the market
- Last patent listed
- June 8, 2026 (expired)
- Exclusivity ends
- August 21, 2028
Tofacitinib questions
How much does tofacitinib cost without insurance?
Pharmacies pay about $62.63 for 30 tablets of tofacitinib 11 mg (24 hr) extended-release tablet ($2.09 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $82.52. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
What is the brand name of tofacitinib?
Tofacitinib is sold as Xeljanz. The generic has the same active ingredient and usually costs far less.
Is tofacitinib in shortage?
No shortage is reported for tofacitinib right now. We check the national shortage list every day.
Has tofacitinib been recalled?
No recalls are on record for tofacitinib.
When did the tofacitinib label last change?
The official label was last updated on July 24, 2026 (version 1). See what changed.
Does Medicare have a negotiated price for Tofacitinib?
Yes - Xeljanz was selected and its negotiated price starts January 1, 2028.
Talk about tofacitinib
No comments yet. Questions, tips, what worked for you - start the conversation.